Campora E, Esposito M, Civalleri D, Gogioso L, Decian F, Balletto N, Falcone A, Nobile M T, Parodi B, Cafaggi S
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Anticancer Res. 1987 Jul-Aug;7(4B):829-32.
Seven patients with advanced colon cancer, refractory to conventional chemotherapy, and malignant disease confined to the intra-abdominal space received a total of 24 consecutive courses of ip 5-Fluorouracil (5-FU). 5-FU 1000 mg was administered in 2 L of warm (37 degrees C) dialysate daily for five consecutive days every 28 days. 5-FU concentrations in serum, peritoneal fluid and urine were measured by high pressure liquid chromatography (HPLC). The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min. The mean peritoneal AUC was 450 +/- 165 times greater than the mean serum AUC. Ip 5-FU treatment is well tolerated, can be safely administered on an outpatient basis and produces a significant pharmacological advantage over conventional routes of administration.
7例晚期结肠癌患者,对传统化疗耐药,且恶性疾病局限于腹腔内,共接受了24个连续疗程的腹腔内5-氟尿嘧啶(5-FU)治疗。每28天连续5天每天在2升温热(37摄氏度)透析液中给予5-FU 1000毫克。通过高压液相色谱法(HPLC)测量血清、腹腔液和尿液中的5-FU浓度。5-FU从腹腔液中的平均消除半衰期为1.6小时,平均通透面积乘积(PA)为22.4毫升/分钟。腹腔平均曲线下面积(AUC)比血清平均AUC大450±165倍。腹腔内5-FU治疗耐受性良好,可在门诊安全给药,与传统给药途径相比具有显著的药理学优势。